Delving into the Latest Updates on Gufic Biosciences Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Hormone

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Hormone	1

AbstractAim:To compare the safety and efficacy of Stunnox with the international brand of botulinum toxin A on lateral canthal lines.Materials and Methods:This was a nonrandomized, controlled, pilot, split-face study in 47 patients who were given two brands of Botulinum toxin A for the treatment of lateral canthal lines for 12 weeks. Evaluation of lines was assessed with grades of 0 (none), 1 (mild), 2 (moderate), and 3 (severe) at a maximum smile and rest by using ANTERA 3D camera.Results:There was a statistical significance in lateral canthal lines wrinkles reduction on the Stunnox sides compared to pretreatment and at weeks 4, 8, and 12, respectively (all P < 0.05). The wrinkle reduction was similar to the effects of the control internationally available brand of botulinum toxin A. The clinical improvement of lateral canthal line wrinkles was greatest at 4 weeks after injection and the improvement lasted until 12 weeks of treatment with no adverse events observed.Conclusion:In this split-face study, Stunnox botulinum toxin A showed a moderate but significant wrinkle-soothing effect without obvious side effects on the lateral canthal.

30 Jul 2022·Indian Journal of Critical Care Medicine

A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients

Article

Author: Shetty, Adarsh ; Manjunath, B G ; Sathe, Prachee ; Chandrakant, Nirhali Sonali ; Darnule, Rahul Ashok

BackgroundFrom an epidemic outbreak, coronavirus disease-2019 (COVID-19) has quickly developed. Thymosin α1 (Tα1) has the ability to boost the T-cell numbers, support T-cell differentiation, maturation, and reduce cell apoptosis. In this study, we have investigated the efficacy and safety of Tα1 in moderate-to-severe COVID-19 patients.Patients and methodsIn this double-blind, multicenter, two-arm, randomized, placebo-controlled, phase III clinical study, patients were randomized to receive either Tα1 or placebo in combination with standard of care (SOC). The data on all-cause mortality, clinical progression/deterioration, duration of hospital/intensive care unit (ICU) stay, and safety data were collected. The patients were telephonically followed up on Day 28.ResultsA total of (n = 105) COVID-19 patients were included in the study, of which 40 and 65 were severe and moderate, respectively. Thymosin arm (11.1%) had a statistically lower death rate in comparison to the placebo arm (38.5%). A total of 67 adverse events were reported in 42 patients among 105 dosed patients during the study. Among them, 43 adverse events were of mild in nature, 16 adverse events were of moderate in nature, and 8 serious adverse events (death) occurred during the study.ConclusionThis study provides evidence that Tα1 can lower death rate in severe COVID-19 patients, reduce the load on hospitals by shortening the required number of days of hospitalization and help in abbreviating the requirement of oxygen support by positively impacting the recovery rate and time taken for recovery.How to cite this articleShetty A, Chandrakant NS, Darnule RA, Manjunath BG, Sathe P. A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients. Indian J Crit Care Med 2022;26(8):913-919.

International Journal of Research and Review

Dalbavancin, a Second Generation Lipoglycopeptide is a New Addition to Therapy Armamentarium

Author: M. Gunjikar, Bhagyashree ; Manickam, Jawahar ; Ghude, Dilip

Gram-positive infections with widespread developing resistance have posed considerable challenges to the long stay of antimicrobials in the market. Also, there has been a dearth in the provision of a suitable antimicrobial to treat the evolving resistance. Dalbavancin a 2nd generation lipoglycopeptide has shown its activity against gram-positive and multidrug resistant isolates. Owing to a favorable pharmacokinetic profile and supporting evidence this drug moiety has been used as long-term therapy for various indications. These indications include infective endocarditis (IE), osteomyelitis, bloodstream infections, and prosthetic joint infections. However, it is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) only for acute bacterial skin and skin structure infections (ABSSSIs). Dalbavancin can be a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections and ‘niche’ but important indications. This systematic review demonstrates comparative microbiology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of dalbavancin. Additionally, it highlights past, present, and upcoming evidence of real-world use of dalbavancin alone or in combination with different indications. Keywords: Dalbavancin, Acute bacterial skin and skin structure infections, Gram-positive, Long-term, and pharmacokinetics.

100 Deals associated with Gufic Biosciences Ltd.

Login to view more data

100 Translational Medicine associated with Gufic Biosciences Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data